FDA, Using Precision Medicine, Triples Number of Cystic Fibrosis Mutations Kalydeco May Treat
The U.S. Food and Drug Administration (FDA) has expanded its approval of Kalydeco (ivacaftor) to include cystic fibrosis (CF) patients with one of 23 additional rare mutations — more than tripling the number of mutations the oral drug may be used to treat from 10 to 33. But the decision’s…